Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03301181 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03301181 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 40 participants.
The verdict
NCT03301181, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Phase 1 study in healthy subjects to determine the effect of rifampin (Part A) or itraconazole (Part B) on the pharmacokinetics of BGB-3111
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG BGB-3111 (Arm A)
- DRUG BGB-3111 (Arm B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2017-11-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03301181
The ClinicalTrials.gov registry entry for NCT03301181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Rifampin is the first listed.
NCT03301181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03301181 about?
NCT03301181 is a clinical study titled "Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects". Phase 1 study in healthy subjects to determine the effect of rifampin (Part A) or itraconazole (Part B) on the pharmacokinetics of BGB-3111
What is the current status of trial NCT03301181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-09-18. Estimated completion is 2017-11-13.
What interventions are being tested in trial NCT03301181?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), BGB-3111 (Arm A) (DRUG), BGB-3111 (Arm B) (DRUG).
Who is sponsoring clinical trial NCT03301181?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.